Walleye Capital LLC Vertex Pharmaceuticals Inc Put Options Transaction History

Walleye Capital LLC

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $8.96 Million - $11.1 Million	-22,800 Reduced 54.94%	18,700 $8.77 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $13 Million - $14.2 Million	31,900 Added 332.29%	41,500 $17.3 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $15.4 Million - $18.4 Million	-44,800 Reduced 82.35%	9,600 $3.91 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $17 Million - $18.3 Million	50,400 Added 1260.0%	54,400 $18.9 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $754,608 - $844,584	-2,400 Reduced 37.5%	4,000 $1.41 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $169,938 - $193,860	600 Added 10.34%	6,400 $2.02 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $57,152 - $64,296	200 Added 3.57%	5,800 $1.67 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.53 Million - $1.71 Million	5,600 New	5,600 $1.62 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $428,412 - $562,020	-1,900 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $2.3 Million - $2.85 Million	-11,500 Reduced 85.82%	1,900 $452,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $616,827 - $828,467	3,700 Added 38.14%	13,400 $2.93 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $448,821 - $505,143	2,700 Added 38.57%	9,700 $1.64 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $1.02 Million - $1.18 Million	6,200 Added 775.0%	7,000 $1.28 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $130,983 - $155,760	800 New	800 $147,000

1,707

226M

1.2M

1.59M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.